# Intermittent (oral) Rybelsus / Semaglutide use in healthy individuals? **URL:** \ **Category:** General\ **Created:** [January 30, 2022, 7:20am UTC](https://www.rapamycin.news/t/intermittent-oral-rybelsus-semaglutide-use-in-healthy-individuals/642 "2022-01-30T07:20:20Z")\ **Posts on this page:** 1\ **Showing post:** 252
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 11, 2024, 7:07am UTC](https://www.rapamycin.news/t/intermittent-oral-rybelsus-semaglutide-use-in-healthy-individuals/642/252 "2024-05-11T07:07:58Z")
Seems like the first post here may have been prescient. This may get interesting as the research progresses: > [@Will the GLP-1 drugs promote longevity and healthspan?](https://www.rapamycin.news/t/will-the-glp-1-drugs-promote-longevity-and-healthspan/13884): > > Functional and multi-omic aging rejuvenation with GLP-1R agonism Importantly, the beneficial effects are specific to aged mice, not young adults, and are achieved with a low dosage of GLP-1RA which has a negligible impact on food consumption and body weight. The molecular rejuvenation effects exhibit organ-specific characteristics, which are generally heavily dependent on hypothalamic GLP-1R. We benchmarked the GLP-1RA age-counteracting effects against those of mTOR inhibition, a well-established anti-aging intervention, observing a strong resemblance across the two strategies. --- _[View the full topic](https://www.rapamycin.news/t/intermittent-oral-rybelsus-semaglutide-use-in-healthy-individuals/642)._